(RTTNews) - Creative Medical Technology Holdings, Inc. (CELZ), a clinical-stage biotechnology company specializing in regenerative medicine, announced on Thursday promising initial results from its ongoing Phase 1/2 clinical trial of CELZ-201-DDT, a stem cell-based therapeutic for chronic back pain caused by degenerative disc disease or DDD.
The first cohort, which included 10 participants (8 receiving CELZ-201-DDT and 2 receiving placebo), completed the study phase without any dose-limiting toxicities or serious adverse events. Preliminary blinded data showed encouraging signs of therapeutic potential, with CELZ-201-DDT alleviating back pain and potentially restoring functionality in patients.
Based on a thorough safety review, the independent Data Safety Monitoring Board or DSMB has recommended the trial proceed to the next cohort as planned.
Key highlights from the first cohort include:
CELZ-201-DDT demonstrated an excellent safety profile with no serious adverse events.
Early data suggest CELZ-201-DDT shows potential in improving symptoms of chronic back pain associated with DDD.
The DSMB has endorsed the continuation of the trial.
Enrollment for the second cohort is expected to begin in the first quarter of 2025.
The ongoing data will guide future clinical and regulatory strategies for the treatment.
Creative Medical Technology Holdings remains committed to advancing regenerative therapies for chronic conditions, with CELZ-201-DDT representing a promising non-opioid treatment option for chronic back pain caused by degenerative disc disease.
Currently, CELZ is trading at $3.16 down by 2.10%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
